|Appears in Collections:||Aquaculture Book Chapters and Sections|
|Peer Review Status:||Refereed|
|Title:||Chapter 2 – Utility of greater wax moth larva (galleria mellonella) for evaluating the toxicity and efficacy of new antimicrobial agen|
|Authors:||Desbois, Andrew P|
Coote, Peter J
|Citation:||Desbois AP & Coote PJ (2012) Chapter 2 – Utility of greater wax moth larva (galleria mellonella) for evaluating the toxicity and efficacy of new antimicrobial agents. In: Laskin AI, Sariaslani S, Gadd GM (ed.). Advances in Applied Microbiology, Volume 78. Advances in Applied Microbiology, 78, Amsterdam: Elsevier, pp. 25-5|
|Keywords:||Wax moth larva|
Minimum inhibitory concentration
|Series/Report no.:||Advances in Applied Microbiology, 78|
|Abstract:||There is an urgent need for new antimicrobial agents to combat infections caused by drug-resistant pathogens. Once a compound is shown to be effective in vitro, it is necessary to evaluate its efficacy in an animal infection model. Typically, this is achieved using a mammalian model, but such experiments are costly, time consuming, and require full ethical consideration. Hence, cheaper and ethically more acceptable invertebrate models of infection have been introduced, including the larvae of the greater wax moth Galleria mellonella. Invertebrates have an immune system that is functionally similar to the innate immune system of mammals, and often identical virulence and pathogenicity factors are used by human pathogenic microbes to infect wax moth larvae and mammals. Moreover, the virulence of many human pathogens is comparable in wax moth larvae and mammals. Using key examples from the literature, this chapter highlights the benefits of using the wax moth larva model to provide a rapid, inexpensive, and reliable evaluation of the toxicity and efficacy of new antimicrobial agents in vivo and prior to the use of more expensive mammalian models. This simple insect model can bridge the gap between in vitro studies and mammalian experimentation by screening out compounds with a low likelihood of success, while providing greater justification for further studies in mammalian systems. Thus, broader implementation of the wax moth larva model into anti- infective drug discovery and development programs could reduce the use of mammals during preclinical assessments and the overall cost of drug development.|
|Rights:||The publisher has not responded to our queries therefore this work cannot be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author. You can only request a copy if you wish to use this work for your own research or private study.|
|Desbois and Coote 2012.pdf||227.78 kB||Adobe PDF||Under Embargo until 31/12/2999 Request a copy|
Note: If any of the files in this item are currently embargoed, you can request a copy directly from the author by clicking the padlock icon above. However, this facility is dependent on the depositor still being contactable at their original email address.
This item is protected by original copyright
Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
If you believe that any material held in STORRE infringes copyright, please contact firstname.lastname@example.org providing details and we will remove the Work from public display in STORRE and investigate your claim.